Welcome to our dedicated page for TREVENA news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on TREVENA stock.
Trevena, Inc. (Nasdaq: TRVN) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies targeting G protein-coupled receptors (GPCRs). The company's mission is to improve patient outcomes and reduce healthcare costs through novel therapies. Trevena's pipeline includes four key drug candidates:
- TRV130 (OLINVYK®): An FDA-designated breakthrough therapy for the intravenous treatment of acute moderate to severe pain, currently in Phase 3 testing. Recently, OLINVYK's effectiveness was assessed in the VOLITION study, showing promising results in terms of respiratory, gastrointestinal, and cognitive function outcomes in postoperative settings.
- TRV027: Evaluated in a Phase 2b study for treating acute heart failure, this candidate aims to address unmet needs in cardiovascular treatment.
- TRV734: Completed Phase 1 testing for the oral treatment of acute and chronic pain, TRV734 seeks to provide a non-opioid alternative for pain management.
- TRV250: In preclinical development for migraine treatment, focusing on innovative solutions for CNS disorders.
Trevena's pipeline is based on Nobel Prize-winning research, emphasizing its commitment to pioneering medical advancements. The company has collaborations with prominent institutions like Wake Forest Baptist Health and the Cleveland Clinic, ensuring rigorous evaluation and development of its therapies. Trevena is also exploring TRV045 for diabetic neuropathic pain and epilepsy, showcasing the potential impact beyond pain management.
Financially, Trevena has shown resilience, recently reporting a net loss reduction and strengthening its balance sheet with significant capital injections. The company continues to focus on strategic partnerships and innovative research to maintain its competitive edge in the biopharmaceutical industry.
For more information, please visit www.Trevena.com.
Trevena, Inc. (Nasdaq: TRVN) plans to release its first-quarter financial results for 2022 on May 11, 2022, before the market opens. A conference call and webcast will be held at 8:00 a.m. ET featuring key company executives. Trevena is focused on developing innovative medicines for CNS disorders and currently has one approved product, OLINVYK, for managing acute pain. The company is also developing four investigational drug candidates targeting various conditions.
On April 20, 2022, Trevena announced favorable results from a study on its drug OLINVYK (oliceridine) in elderly and overweight individuals, indicating a significantly reduced impact on respiratory function compared to IV morphine. Conducted in collaboration with Leiden University Medical Center, the study demonstrated that both drugs provided comparable pain relief, but OLINVYK exhibited better respiratory safety. Results are consistent with earlier studies in younger subjects, suggesting OLINVYK's potential for safer use in at-risk populations.
Trevena, Inc. (Nasdaq: TRVN) announced a significant financing milestone, receiving the first $15 million tranche from R-Bridge Healthcare Fund as part of a royalty-based agreement. This deal includes further funding of $15 million upon the first commercial sale of OLINVYK® in China and an additional $10 million contingent on achieving specific milestones. Trevena retains all milestone payments from its partner, Jiangsu Nhwa Pharmaceutical, including a critical $3 million milestone tied to OLINVYK's approval in China by year-end 2023.
Trevena, Inc. (Nasdaq: TRVN) reported on its participation in recent medical meetings focusing on OLINVYK® (oliceridine) injection for acute pain management. The company attended the 47th Annual Regional Anesthesiology and Acute Pain Medicine Meeting and the American Burn Association Annual Meeting, where OLINVYK data was highlighted, including a President's Choice abstract presentation on its low incidence of opioid-induced respiratory depression. OLINVYK, approved by the FDA in August 2020, is indicated for adults needing intravenous opioid analgesics.
Trevena, Inc. (Nasdaq: TRVN) announced a royalty-based financing deal with R-Bridge Healthcare Fund, securing an initial $15 million, with an additional $15 million contingent on OLINVYK's first commercial sale in China. The deal includes a 4% net revenue interest in U.S. sales of OLINVYK, capped at $10 million if Chinese approval is received by year-end 2023. Trevena retains its milestones from its partnership with Jiangsu Nhwa Pharmaceutical, including a $3 million milestone upon Chinese approval of OLINVYK. The financing is expected to enhance Trevena's financial position.
Trevena, Inc. (TRVN) reported its financial results for Q4 and full year 2021, revealing a year-end cash balance of $66.9 million, enough to fund operations through Q4 2022. The company highlighted the commercial launch of OLINVYK, with significant engagement with over 700 accounts. Patricia Drake was appointed as Chief Commercial Officer, bringing extensive experience. Positive topline data from an OLINVYK study indicated a statistically significant reduction in respiratory depression compared to IV morphine. A $40 million financing deal was secured for OLINVYK royalties from Jiangsu Nhwa in China.
Trevena, Inc. (Nasdaq: TRVN) announced that it will release its financial results for Q4 and full year 2021 on March 31, 2022, before market opening. The conference call is scheduled for the same day at 8:00 a.m. ET, featuring remarks from top executives including the CEO and CFO. Trevena has one approved product, OLINVYK, and a pipeline that includes four investigational drug candidates targeting various CNS disorders. A live webcast will accompany the call and will be accessible on the company’s website.
CHESTERBROOK, Pa., Feb. 3, 2022 (GLOBE NEWSWIRE) -- Trevena (Nasdaq: TRVN) will present a corporate overview at the BIO CEO & Investor Conference from February 14-17, 2022. Carrie Bourdow, President & CEO, leads the presentation, which includes a pre-recorded overview and one-on-one virtual meetings. The presentation will be available on-demand starting February 11, 2022. Trevena's pipeline includes innovative treatments for CNS disorders, such as OLINVYK for acute pain and investigational candidates like TRV250 for migraines and TRV734 for opioid use disorder.
Trevena, Inc. (Nasdaq: TRVN) announced that China’s National Medical Products Administration has accepted the New Drug Application (NDA) for OLINVYK (oliceridine injection), submitted by its partner Jiangsu Nhwa Pharmaceutical. This follows a Phase 3 bridging trial demonstrating the safety and efficacy of OLINVYK compared to IV morphine in Chinese patients. Trevena is eligible for future milestone payments and a 10% royalty on net sales in China upon approval and commercialization.
Trevena, Inc. (Nasdaq: TRVN) has announced the participation of CEO Carrie Bourdow and CFO Barry Shin in three virtual investor conferences this January. The conferences include the LifeSci Partners Annual Corporate Access Event from January 5-7, where a panel discussion on biopharmaceutical commercial launches will take place on January 5 at 7:30 AM ET. The company will also participate in the H.C. Wainwright BioConnect Virtual Conference from January 10-12 and BIO Partnering at JPM from January 10-13. Trevena focuses on CNS disorders and has one approved product, OLINVYK®.
FAQ
What is the current stock price of TREVENA (TRVN)?
What is the market cap of TREVENA (TRVN)?
What is Trevena, Inc.?
What is OLINVYK®?
What recent developments has Trevena announced?
What is TRV045?
How is Trevena's financial performance?
What types of products does Trevena develop?
Are Trevena's products FDA approved?
What partnerships does Trevena have?
Where can I find more information about Trevena’s research?
What are the primary focus areas of Trevena's research?
